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Differential proteomics highlights macrophage-
specific responses to amorphous silica
nanoparticles†
Bastien Dalzon,a Catherine Aude-Garcia,a Véronique Collin-Faure,a Hélène Diemer,b
David Béal,c Fanny Dussert,c Daphna Fenel,d Guy Schoehn,d Sarah Cianférani,b
Marie Carrièreb and Thierry Rabilloud *a
The technological and economic benefits of engineered nanomaterials may be offset by their adverse
effects on living organisms. One of the highly produced nanomaterials under such scrutiny is amorphous
silica nanoparticles, which are known to have an appreciable, although reversible, inflammatory potential.
This is due to their selective toxicity toward macrophages, and it is thus important to study the cellular
responses of this cell type to silica nanoparticles to better understand the direct or indirect adverse
effects of nanosilica. We have here studied the responses of the RAW264.7 murine macrophage cells and
of the control MPC11 plasma cells to subtoxic concentrations of nanosilica, using a combination of pro-
teomic and targeted approaches. This allowed us to document alterations in the cellular cytoskeleton, in
the phagocytic capacity of the cells as well as their ability to respond to bacterial stimuli. More surprisingly,
silica nanoparticles also induce a greater sensitivity of macrophages to DNA alkylating agents, such as
styrene oxide, even at doses which do not induce any appreciable cell death.
1. Introduction
Silica-based particulate materials are highly used as abrasives
both in the industry and in consumer products such as tooth-
pastes, as well as reinforcing agents (e.g. as mineral charges in
tires) or in the high-tech industry (e.g. in photovoltaics or as
high precision molding agents). These wide uses increase the
exposure potential of individuals to silica, which poses in turn
the problem of the direct and indirect toxicity of silica. In this
frame, crystalline silica has long been known as the causative
agent of silicosis and is therefore highly regulated. Conversely,
amorphous silica has been demonstrated to induce only a
transient and reversible inflammation upon pulmonary
exposure,1–3 and is therefore considered as safer. However, the
amorphous silica-induced inflammation can be pronounced3
and are found in vivo and in vitro as well.4
Considerable work has been devoted to the analysis of the
toxicity of amorphous silica in vitro, and strong directions have
emerged. One of them is the differential sensitivity of different
cell types to amorphous silica,5–8 and the other one is the
influence of the size of the nanoparticles.5,9–15 However, it has
been shown that within a given cell type, the type of response
is similar for particles of different sizes.16
Regarding the toxic mechanisms induced by amorphous
silica, oxidative stress effects have been demonstrated,17–20
and seems to be linked more to direct ROS generation than to
an indirect mechanism via glutathione depletion.21,22
Genotoxicity has also been observed,23–27 and is likely to be
linked to the oxidative stress mentioned before.
Beyond these toxic mechanisms, it is interesting to under-
stand more widely the cellular responses at sub-toxic concen-
trations of amorphous silica, as they may be linked to the
inflammatory responses observed in vitro,8,11,14,17,28–30 or
in vivo.2
One of the emerging mechanisms at play is the autophagy/
inflammasome axis,31–36 which clearly plays a pivotal role in
the induction of pro-inflammatory cytokines by silica.
However there are clearly other cellular responses to amor-
phous silica, as exemplified by transcriptomic studies,16,37,38
and deciphering these responses may help to understand
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cross toxicities between amorphous silica and metals39,40 or
organic compounds.41
In this frame, proteomic studies can be useful in addition to
transcriptomics, and have indeed been used to study cellular
responses to amorphous silica, on keratinocytes42 and in lung
epithelial cells.43 We have thus decided to perform a proteomic
study of the effects of amorphous silica on macrophages, using
the well documented RAW264.7 line.44 As the cellular responses
have been reported to be largely conserved across the size range
for silica16 we have focused our study on a single precipitated
silica nanoparticle, previously used in ecotoxicology.45 In order
to take into account the cell type-specific responses, we
have performed this study simultaneously on the
RAW264.7 macrophage cell line and in a control, less silica-
sensitive cell line of the same genotype and of hematopoietic
origin, the MPC11 plasmacytoma cell line. This cell line grows
at the same speed as the RAW264.7 line in the same culture
medium, and also has a similar nucleocytoplasmic ratio.
2. Experimental
Most experiments have been performed essentially as
described in previous publications.46–48 Details are given here
for the sake of the consistency of the paper. All biological
experiments were carried out at least on three independent
biological replicates.
2.1. Nanoparticles
The silica nanoparticles (Ludox TMA®) were purchased from
Sigma, directly as a concentrated suspension. This suspension
was diluted to a silica concentration of 1 mg ml−1 in distilled
water just prior to use. The actual size of the particles was
determined after dilution in water or in complete culture
medium by dynamic light scattering, using a Wyatt Dynapro
Nanostar instrument. The morphology of samples was
observed by TEM (Transmission Electron Microscopy).
Samples were absorbed to the clean side of a carbon film on
mica and transferred to a 400-mesh copper grid. The images
were taken under low dose conditions (<10 e− Å−2) at a magni-
fication of 11k×, 13k×, 23k× and 30k× with defocus values
between 1.2 and 2.5 μm on a Tecnai 12 LaB6 electron micro-
scope at 120 kV accelerating voltage using a CCD Camera
Gatan Orius 1000.
2.2. Cell culture
The mouse macrophage cell line RAW264.7 and the mouse
plasmacytoma cell line MPC11 were obtained from the
European Cell Culture Collection (Salisbury, UK). The cells
were cultured in RPMI 1640 medium supplemented with 10%
fetal bovine serum (FBS). Cells were seeded at 200 000 cells per
ml and harvested at 1 000 000 cells per ml. For treatment with
nanoparticles, cells were seeded at 500 000 cells per ml. They
were treated with nanoparticles on the following day and har-
vested after a further 24 hours in culture. Cell viability was
measured by a dye exclusion assay, either with eosin
(1 mg ml−1)49 under a microscope or with propidium iodide
(1 µg ml−1)50 in a flow cytometry mode. For cross toxicity experi-
ments, the cells were first exposed to silica alone for 6 hours.
The tested inhibitors or toxicants were then added for an
additional 18 hours and the cell viability measured afterwards.
2.3. Phagocytosis and particle internalization assay
The phagocytic activity was measured using fluorescent latex
beads (1 µm diameter, green labelled, catalog number L4655
from Sigma). The beads were pre-incubated at a final concen-
tration of 55 µg mL−1 for 30 minutes at 37 °C in PBS/FBS (v/v).
Then, they were incubated with cells (5 µg mL−1) for 2 h
30 min at 37 °C. The cells were harvested and washed with
PBS. The cells were resuspended by vortexing with addition of
3/4 water volume and then 1/4 NaCl (35 mg mL−1) volume was
added under vortexing in order to clean the cell surface of
adsorbed particles. The cells were harvested in PBS with propi-
dium iodide (1 µg mL−1). Viability and phagocytic activity were
measured simultaneously by flow cytometry on a FacsCalibur
instrument (Beckton Dickinson). The dead cells (propidium
positive) were excluded from the analysis.
For the internalization assay, latex nanoparticles (fluo-
rescent green, from Sigma) were used. The nanoparticles were
added directly to the serum-containing cell culture medium
and left for 24 hours in contact with the cells. Post-exposure
cell harvesting, treatment and analysis were performed similar
to the phagocytosis assay.
2.4. Mitochondrial transmembrane potential measurement
The mitochondrial transmembrane potential was assessed by
Rhodamine 123 uptake. The cells were incubated with
Rhodamine 123 (80 nM) for 30 minutes at 37 °C, 5% CO2 then
rinsed twice in cold glucose (1 mg mL−1)–PBS (PBSG) and har-
vested in cold PBSG supplemented with propidium iodide (1
µg mL−1). The mitochondrial potential of cells was analysed by
flow cytometry on a FacsCalibur instrument (Beckton
Dickinson). The dead cells (propidium positive) were excluded
from the analysis. The low Rhodamine concentration was used
to avoid intramitochondrial fluorescence quenching that would
result in a poor estimation of the mitochondrial potential.51
2.5. Enzyme assays
The enzymes were assayed according to published procedures.
Isocitrate dehydrogenase was assayed by a coupled assay using
nitro blue tetrazolium as the final acceptor and phenazine
methosulfate as a relay.52 Biliverdin reductase was assayed
directly for the NADPH-dependent conversion of biliverdin
into bilirubin, followed at 450 nm.53 Lactoylglutathione lyase
activity was followed at 240 nm as previously described.54
The cell extracts for enzyme assays were prepared by lysing
the cells for 20 minutes at 0 °C in 20 mM Hepes (pH 7.5),
2 mM MgCl2, 50 mM KCl, 1 mM EGTA, 0.15% (w/v)
tetradecyldimethylammonio propane sulfonate (SB 3–14), fol-
lowed by centrifugation at 15 000g for 15 minutes to clear the
extract. The protein concentration was determined by a dye-
binding assay.55
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2.6. NO production and cytokine production
The cells were grown to confluence in a 6 well plate and pre-
treated with silica for 6 hours. Then half of the wells were
treated with 100 ng ml−1 LPS (from salmonella, purchased
from Sigma), and arginine monohydrochloride was added to
all the wells (5 mM final concentration) to give a high concen-
tration of substrate for the nitric oxide synthase. After
18 hours of incubation, the cell culture medium was recovered,
centrifuged at 10 000g for 10 minutes to remove cells and
debris, and the nitrite concentration in the supernatants was
read at 540 nm after addition of an equal volume of Griess
reagent and incubation at room temperature for 30 minutes.
For cytokine production, a commercial kit (BD Cytometric
Bead Array, catalog number 552364 from BD Biosciences) was
used. The supernatant of cells treated with NP-SiO2 was recov-
ered and the kit protocol was followed.
2.7. F-actin staining
The experiments were performed essentially as previously
described.56 The cells were cultured on coverslips placed in
6-well plates and exposed to silica or latex nanoparticles for
24 h at 37 °C. At the end of the exposure time, the cells were
washed twice for 5 min at 4 °C in PBS and fixed in 4% parafor-
maldehyde for 30 min at room temperature. After two washes
(5 min/4 °C in PBS), they were permeabilized in 0.1% Triton
X-100 for 5 min at room temperature. After two more washes
in PBS, 500 nM Phalloidin-Atto 550 (Sigma) was added to the
cells and left undisturbed for 20 min at room temperature in
the dark. Coverslip-attached cells were washed, placed on
microscope slides (Thermo Scientific) using a Vectashield
mounting medium containing DAPI (Eurobio) and imaged
using a Zeiss LSM 800 confocal microscope. The images were
processed using ImageJ software.
2.8. RT-qPCR
RNA was extracted using the GenElute™ mammalian total
RNA miniprep kit with the optional DNase treatment step,
then reverse-transcribed using SuperScript III Reverse
Transcriptase (Life Technologies). RNA concentration and
purity were assessed by measuring Abs 260/Abs 280 and Abs
260/Abs 230 absorbance ratios using a Nanodrop ND-1000
spectrophotometer (Thermo Fisher Scientific). Then, cDNA
from each of the three biological replicates for each exposure
condition was loaded in duplicate on a 96-well plate. Primer
sequences are given in ESI Table 2.† Their efficiencies were
experimentally checked for compliance using a mix of all
samples, with a quality criterion of 2 ± 0.3. Quantitative PCR
was performed on a MX3005P Multiplex Quantitative PCR ther-
mocycler (Stratagene), using the following thermal cycling
steps: 95 °C for 5 min, then 95 °C for 15 s, 55 °C for 20 s and
72 °C for 40 s 40 times and finally 95 °C for 1 min, 55 °C for
30 s and 95 °C for 30 s for the dissociation curve. Cq was deter-
mined using the Mx-Pro 3.20 software with default settings.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and 18S
ribosomal 1 (S18) were chosen as reference genes for normali-
zation, validated using BestKeeper.57 mRNA expression ana-
lysis, normalization and statistical analysis were performed
using REST2009 software58 using the ΔΔCq method and a
pair-wise fixed reallocation randomization test.
2.9. Proteomics
The 2D gel based proteomic experiments were essentially
carried out as previously described,46 at least on independent
biological triplicates. However, detailed materials and
methods are provided for the sake of paper consistency.
2.9.1. Sample preparation. The cells were collected by
scraping, and then washed three times in PBS. The cells were
then washed once in TSE buffer (10 mM Tris-HCl (pH 7.5),
0.25 M sucrose, 1 mM EDTA), and the volume of the cell pellet
was estimated. The pellet was resuspended in its own volume
of TSE buffer. Then 4 volumes (respective to the cell suspen-
sion just prepared) of concentrated lysis buffer (8.75 M urea,
2.5 M thiourea, 5% w/v CHAPS, 6.25 mM TCEP-HCl, 12.5 mM
spermine base) were added and the solution was left undis-
turbed for extraction at room temperature for 1 hour. The
nucleic acids were then pelleted by ultracentrifugation
(270 000g at room temperature for 1 h), and the protein con-
centration in the supernatant was determined by a dye-
binding assay.55 Carrier ampholytes (Pharmalytes pH 3–10)
were added to a final concentration of 0.4% (w/v), and the
samples were kept frozen at −20 °C until use.
2.9.2. Isoelectric focusing. Home-made 160 mm long 4–8
linear pH gradient gels59 were cast according to published pro-
cedures.60 Four mm-wide strips were cut, and rehydrated over-
night with the sample, diluted in a final volume of 0.6 ml of
rehydration solution (7 M urea, 2 M thiourea, 4% CHAPS,
0.4% carrier ampholytes (Pharmalytes pH 3–10) and 100 mM
dithiodiethanol).61
The strips were then placed in a Multiphor plate (GE
Healthcare), and IEF was carried out with the following electri-
cal parameters: 100 V for 1 hour, then 300 V for 3 hours, then
1000 V for 1 hour, then 3400 V up to 60–70 kVh. After IEF, the
gels were equilibrated for 20 minutes in 125 mM Tris, 100 mM
HCl, 2.5% SDS, 30% glycerol and 6 M urea.62 They were then
transferred on top of the SDS gels and sealed in place with 1%
agarose dissolved in 125 mM Tris, 100 mM HCl, 0.4% SDS and
0.005% (w/v) bromophenol blue.
2.9.3. SDS electrophoresis and protein detection. Ten
percent gels (160 × 200 × 1.5 mm) were used for protein separ-
ation. The Tris taurine buffer system63 was used and operated
at an ionic strength of 0.1 and a pH of 7.9. The final gel com-
position is thus 180 mM Tris, 100 mM HCl, 10% (w/v) acryl-
amide, and 0.27% bisacrylamide. The upper electrode buffer is
50 mM Tris, 200 mM Taurine, and 0.1% SDS. The lower elec-
trode buffer is 50 mM Tris, 200 mM glycine, and 0.1% SDS.
The gels were run at 25 V for 1 hour, then 12.5 W per gel until
the dye front has reached the bottom of the gel. Detection was
carried out by tetrathionate silver staining.64
2.9.4. Image analysis. The gels were scanned after silver
staining on a flatbed scanner (Epson perfection V750), using a
16 bit grayscale image acquisition. The gel images were then
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analyzed using the Delta 2D software (v 3.6). Spots that were
never expressed above 100 ppm of the total spots were first fil-
tered out. Then, significantly-varying spots were selected on
the basis of their Student’s t-test p-value between the treated
and the control groups. Spots showing a p-value lower than
0.05 were selected. This strategy is used to avoid the use of
arbitrary thresholds, which can result in discarding statisti-
cally-valid relevant changes and including non-valid
changes.65 The false positive concern arising from the multiple
testing problem was addressed using the Storey–Tibshirani
approach,66 as classical statistical filters (e.g. Bonferroni or
Benjamini–Hochberg) yield to over-rejection of valid results.67
Furthermore, we checked that all the spots that we found
through the t-test also had a p < 0.05 in a non-parametric
Mann–Whitney U-test.
2.9.5. Mass spectrometry. The spots selected for identifi-
cation were excised from silver-stained gels and destained with
ferricyanide/thiosulfate on the same day as silver staining in
order to improve the efficiency of the identification
process.68,69 Gel digestion was performed with an automated
protein digestion system, MassPrep Station (Waters, Milford,
USA). The gel plugs were washed twice with 50 µL of 25 mM
ammonium hydrogen carbonate (NH4HCO3) and 50 µL of
acetonitrile. The cysteine residues were reduced by 50 µL of
10 mM dithiothreitol at 57 °C and alkylated by 50 µL of 55 mM
iodoacetamide. After dehydration with acetonitrile, the pro-
teins were cleaved in gel with 10 µL of 12.5 ng µL−1 of modi-
fied porcine trypsin (Promega, Madison, WI, USA) in 25 mM
NH4HCO3. The digestion was performed overnight at room
temperature. The generated peptides were extracted with 30 µL
of 60% acetonitrile in 0.1% formic acid. Acetonitrile was evap-
orated under vacuum before nanoLC-MS/MS analysis.
NanoLC-MS/MS analysis was performed using a
nanoACQUITY Ultra-Performance-LC (Waters Corporation,
Milford, USA) coupled to the Synapt™ High Definition Mass
Spectrometer™ (Waters Corporation, Milford, USA), or to the
TripleTOF 5600 (Sciex, Ontario, Canada).
The nanoLC system was composed of an ACQUITY UPLC®
CSH130 C18 column (250 mm × 75 µm with a 1.7 µm particle
size, Waters Corporation, Milford, USA) and a Symmetry C18
precolumn (20 mm × 180 µm with a 5 µm particle size, Waters
Corporation, Milford, USA). The solvent system consisted of
0.1% formic acid in water (solvent A) and 0.1% formic acid in
acetonitrile (solvent B). 4 µL of sample were loaded into the
enrichment column for 3 min at 5 µL min−1 with 99% of
solvent A and 1% of solvent B. Elution of the peptides was per-
formed at a flow rate of 300 nL min−1 with a 8–35% linear gra-
dient of solvent B in 9 minutes.
The Synapt™ High Definition Mass Spectrometer™ (Waters
Corporation, Milford, USA) was equipped with a Z-spray ion
source and a lock mass system. The system was fully controlled
using MassLynx 4.1 SCN639 (Waters Corporation, Milford,
USA). The capillary voltage was set at 2.8 kV and the cone
voltage at 35 V. Mass calibration of the TOF was achieved
using fragment ions from Glu-fibrino-peptide B on the
[50;2000] m/z range. Online correction of this calibration was
performed with Glu-fibrino-peptide B as the lock-mass. The
ion (M + 2H)2+ at m/z 785.8426 was used to calibrate MS data
and the fragment ion (M + H)+ at m/z 684.3469 was used to
calibrate MS/MS data during the analysis.
For tandem MS experiments, the system was operated with
automatic switching between MS (0.5 s per scan on m/z range
[150;1700]) and MS/MS modes (0.5 s per scan on m/z range
[50;2000]). The two most abundant peptides (intensity
threshold 20 counts per s), preferably doubly and triply
charged ions, were selected on each MS spectrum for further
isolation and CID fragmentation using collision energy profile.
Fragmentation was performed using argon as the collision gas.
Mass data collected during analysis were processed and
converted into .pkl files using ProteinLynx Global Server 2.3
(Waters Corporation, Milford, USA). Normal background sub-
traction type was used for both MS and MS/MS with 5%
threshold and polynomial correction of order 5. Smoothing
was performed on MS/MS spectra (Savitsky-Golay, 2 iterations,
window of 3 channels). Deisotoping was applied for MS
(medium deisotoping) and for MS/MS (fast deisotoping).
The TripleTOF 5600 (Sciex, Ontario, Canada) was operated
in positive mode, with the following settings: ionspray voltage
floating (ISVF) 2300 V, curtain gas (CUR) 10, interface heater
temperature (IHT) 150, ion source gas 1 (GS1) 2, declustering
potential (DP) 80 V. Information-dependent acquisition (IDA)
mode was used with Top 10 MS/MS scans. The MS scan had
an accumulation time of 250 ms in m/z [400;1250] range and
the MS/MS scans 100 ms in m/z [150;1800] range in high sensi-
tivity mode. Switching criteria were set to ions with a charge
state of 2–4 and an abundance threshold of more than 500
counts and exclusion time was set at 4 s. IDA rolling collision
energy script was used for automatically adapting the CE.
Mass calibration of the analyser was achieved using peptides
from digested BSA. The complete system was fully controlled
by AnalystTF 1.7 (Sciex). Raw data collected were processed
and converted with MSDataConverter in .mgf peak list format.
For protein identification, the MS/MS data were interpreted
using a local Mascot server with the MASCOT 2.4.1 algorithm
(Matrix Science, London, UK) against UniProtKB/SwissProt
(version 2016_01, 550299 sequences). Research was carried out
in all species. Spectra were searched with a mass tolerance of
15 ppm for MS and 0.05 Da for MS/MS data, allowing a
maximum of one trypsin missed cleavage.
Carbamidomethylation of cysteine residues and oxidation of
methionine residues were specified as variable modifications.
Protein identifications were validated with at least two pep-
tides with a Mascot ion score above 30.
3. Results
3.1. Nanoparticles characterization and determination of the
effective doses
The amorphous silica nanoparticle used (Ludox™ TMA) was
characterized by several methods, and the results are summar-
ized in Fig. 1 (panels A–C). Spherical nanoparticles were
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obtained (primary diameter 26 ± 4 nm), and the average hydro-
dynamic diameter of these particles, as measured by DLS, was
37 ± 1 nm, with a polydispersity index of 20%. When placed in
serum-containing culture medium the hydrodynamic diameter
immediately increased to 155 ± 7 nm (polydispersity index
25%). The aggregation state increased over time in the serum-
containing medium to up to 365 nm (multimodal) after
24 hours in the medium. Toxicity curves were then determined
on the two cell lines of interest. The LD20, i.e. the concentration
inducing a 20% cell death after 24 hours of treatment, was deter-
mined to be 20 µg ml−1 for the RAW264 cell line and 100
µg ml−1 for the MPC11 cell line (Fig. 1D). These concentrations
were chosen for the subsequent studies, as the LD20 offers a
good compromise between cell viability and biological effect.
In order to determine whether the differences in toxicity
were due to different internalization between the two cell lines
of interest, we tested the internalization of particles in the two
cell lines by using fluorescent latex beads of different dia-
meters (30 and 100 nm). The results, displayed in ESI Fig. 1
and Table 1,† show that silica toxicity parallels the internaliz-
ation capacity of the cells.
3.2. Proteomic studies
In order to gain further insights into the molecular responses
of cells to the amorphous silica nanoparticles, we performed
proteomic studies. We used two different doses for each cell
line. For the RAW264 cell line, 20 µg ml−1 (i.e. the LD20) and
10 µg ml−1 (i.e. a dose where no increased mortality and very
minimal functional effects were observed) were used. For the
MPC11 cell line we used 20 µg ml−1 (i.e. the same dose as on
RAW264, but with no visible macroscopic effects in this case)
and 100 µg ml−1 (i.e. the LD20 for this cell line). This proteo-
mic analysis probed 2590 protein species for the RAW264 cell
line, and 2180 for the MPC11 cell line. The median coefficient
of variation of the spots was 24.5% for the RAW cell line, and
21% for the MPC11 cell line. These coefficients of variation are
in the range of those found in typical 2D DIGE experiments,
where coefficient of variations range from 18 to 28%, depend-
ing on the sample.70–73 The significant protein changes were
detected through the use of a variance-based screen, which
compensates automatically for the variability of each spot, and
enables to take into account small but reproducible changes,
thus avoiding the arbitrary exclusion of changes that can be
biologically meaningful. Through this proteomic screen, we
could detect modulation of proteins belonging to various func-
tional classes, as shown in Fig. 2, Table 1, ESI Table 2 and
Fig. 2–7.† Among the 113 significantly variable spots, 15 were
common between RAW264 and MPC11 and 19 varied for the
two doses of silica in the RAW264 cell line. This means in turn
that the majority of significant variables are specific for the
Fig. 1 Nanoparticles characterization and effects on cell viability. Panel A: TEM image of Ludox TMA silica nanoparticles suspended in water. Panels
B and C: TEM images of Ludox TMA silica nanoparticles suspended in complete culture medium (RPMI 1640 + fetal bovine serum). B: Time in com-
plete medium 30 minutes. C: Time in complete medium 24 hours. Scale bar: 100 µm. Panel D: Effects of Ludox TMA on cell viability on the
RAW264.7 cell line (white bars) and MPC11 cell line (dotted bars).
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Fig. 2 Proteomic analysis of total cell extracts by 2D electrophoresis. Total cell extracts of RAW274.7 cells were separated by two-dimensional gel
electrophoresis. The first dimensions covered a 4–8 pH range and the second dimension a 15–200 kDa range. Total cellular proteins (150 µg) were
loaded on the first dimension gel. A: Gel obtained from control cells. B: Gel obtained from cells treated for 24 hours with 10 µg ml−1 Ludox TMA. C:
Gel obtained from cells treated for 24 hours with 20 µg ml−1 Ludox TMA. The lines and arrows point to spots that show reproducible and statistically
significant changes between the control and nanoparticle-treated cells and to the control neighbor spots in some cases. Spot numbering according
to Table 1.
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RAW264 cell line at the LD20. It can also be noted that most
proteins are present in both the MPC11 and RAW264 cell
lines, although their amounts may be different in the two
lines. This feature has been observed in wider proteomic
screens74 and show that “housekeeping proteins” represent in
fact the vast majority of proteins, at least those detected in pro-
teomic screens.
3.3. Validation studies
The inclusion of small but reproducible protein changes
means in turn that these changes cannot be validated easily by
classical biochemical techniques at the protein expression
level. For example, protein blotting often shows a technical
variability well above 20%, and a response curve often lower
than that of 2D electrophoresis, making this technique unsui-
table for the validation of small fold changes. This renders
functional validation even more necessary, to confirm the bio-
logical relevance of the proteomics-detected protein
modulations.
3.3.1. Enzyme activities. In 2D gel-based proteomics, pro-
teins are often represented by several spots, and it happens fre-
quently that one spot is changed under the biological con-
ditions of interest while the others are more or less constant.
As the different spots correspond to modified forms of the
protein and as protein modifications are known to modulate
enzyme activities (e.g. acetylation75), the correspondence
between spot variations and enzyme activities is far from
obvious and must be verified. We carried out this verification
on three enzymes, namely isocitrate dehydrogenase (spots e1a
and e1b), lactoylglutathione lyase (spot h9) and biliverdin
reductase (spots h3a, h3b and h4). The results, displayed in
Table 2, show that the activity correlates with the spot change
observed on 2D gels for lactoylglutathione lyase. In the case of
isocitrate dehydrogenase, the activity correlates with the
change in the acidic spot corresponding to the enzyme, and
neither with the basic spot nor with the sum of the two spots.
This example demonstrates, if further needed, the interest of a
proteomic analysis taking into account the protein species and
not only the gene product level. In the case of the biliverdin
reductase activity, the situation is more complex. The best cor-
relation is found with a combination of the acidic spot of bili-
verdin reductase A and the spot of biliverdin reductase B. This
is in line with the known role of phosphorylation in the activity
of biliverdin reductase A.76
3.3.2. Cytoskeleton and phagocytosis. Numerous proteins
associated with the actin cytoskeleton emerged from the pro-
teomic screen (see category c in Table 1). This led us to study if
the actin cytoskeleton was altered in macrophages upon treat-
ment with silica nanoparticles, using labelled phalloidin and
confocal microscopy. The results, displayed in Fig. 3, show
that silica nanoparticles induce a decrease in the number of
spikes observed at the surface of the macrophages. This effect
was not due to the internalization of particles per se, as intern-
alization of latex particles did not induce this effect (Fig. 3,
panels D and E).U
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As the actin cytoskeleton is also involved in phagocytosis,
we also tested this macrophage function. The results, dis-
played in Fig. 4A and B, show a moderate decrease in the pro-
portion of phagocytic cells and an almost unchanged phago-
cytic ability for the phagocytosis-positive cell, for the cells
exposed to 20 µg ml−1 silica nanoparticles.
3.3.3. Mitochondrial potential. Numerous mitochondrial
proteins were found in the proteomic study (see category m in
Table 1), some of them implied in energy generation directly
(e.g. the long-chain specific acyl-CoA dehydrogenase (acadl,
spot m9)), the beta subunit of the succinate-CoA ligase [GDP-
forming] (sucb2, spots m1a and m1b) or indirectly through
control of the oxphos complexes (e.g. the mitochondrial
elongation factor Tu (eftu, spot m5), or the ubiquinone biosyn-
thesis protein coq9 (spot m2)). This prompted us to assess the
mitochondrial transmembrane potential. The results, dis-
played in Fig. 4C and D, show no alteration either in the pro-
portion of cells with a normal transmembrane potential or on
the value of the potential. This result is in line with the fact
that most mitochondrial proteins picked in the proteomic
screen show an increase of abundance. This illustrates the fact
that the cells increase the amount of some mitochondrial pro-
teins to compensate for the effects of the silica treatment, and
are thus able to maintain the mitochondrial potential at the
sub-toxic concentrations used.
3.3.4. Effects on signaling pathways. Several proteins
associated with signaling were found modulated upon silica
nanoparticle treatment of macrophages, according to proteo-
mics. We focused on the AMP-activated protein kinase (AMPK
pathway) and on the myeloid differentiation primary response
protein 88 (myd88) pathway.
The activity of the AMPK pathway is controlled by the
STK11/LKB1 kinase,77 whose activity is controlled through the
formation of a ternary LKB1-STRAD-CAB39/Mo25 complex.78
In this model, a decrease in the calcium binding protein 39
(CAB39/Mo25) should result in a decrease of the LKB1 activity,
resulting in turn in a decrease of the AMPK activity.
Macrophages respond to silica nanoparticles by decreasing the
amount of CAB39/Mo25 (spot s1) and thus putatively decreas-
ing the activity of the AMPK pathway. It is also worth noting
that macrophages also respond to silica nanoparticles by a
strong decrease of adenosine kinase (adk, spot r9) whose
product is AMP, i.e. another activator of AMPK.
We thus tested if a pharmacological inhibition of AMPK
would alter cell survival after treatment with silica nano-
particles. The results, displayed in Fig. 5A, show that inhi-
bition of the AMPK pathway dramatically increases cell survi-
val upon treatment with silica.
The myd88 pathway is involved in the transduction of the
signals produced by activation of most Toll like receptors
(TLR).79 Consequently, a decrease in myd88, as we observed in
our proteomic screen (spot i3), should result in a lesser
efficiency of the TLR pathways and thus to decreased
responses when the TLR are stimulated. To test this hypo-
thesis, we used the classical lipopolysaccharide (LPS)-induced
NO production, linked to the stimulation of TLR4. The results
of these experiments, displayed in Fig. 5B, show a progressive
decline of the LPS-induced NO production when cells are
treated with silica nanoparticles. This effect was also observed
for the production of interleukin 6, while Tumor Necrosis
Factor alpha (TNF-alpha) did not show the same response
(Fig. 5C and D).
3.3.5. Effects on DNA. Among the proteins modulated in
response to silica nanoparticles, a few are associated with DNA
replication and DNA repair. We thus first checked if DNA
damage was observable in silica treated RAW264.7 cells. The
results, displayed in ESI Fig. 8,† show that treatment of
RAW264.7 cells with 20 µg ml−1 silica induces an increase in
DNA damage, as previously detected in other cell types6 and/or
with larger silica particles.24 One of the modulated proteins is
the 2′-deoxynucleoside 5′-phosphate N-hydrolase 1 (DNPH1,
spot d3), a protein cleaving off the base from deoxyribonucleo-
tides, independently from the nature of the base, although the
kinetics of the cleavage may differ from one nucleotide to
another.80–82 In the context of nucleotide excision repair,
whose end products are nucleotides, the role of such an
enzyme is to remove the damaged bases from the nucleotides,
so that damaged nucleotides cannot re-enter the salvage
pathway and be re-incorporated into DNA.
Table 2 Enzyme activities measured in control cell extracts and in
extracts prepared from cells treated for 24 hours with either 10 µg ml−1
or 20 µg ml−1 silica nanoparticles. The activities are expressed in units
per mg protein, the unit being defined as 1 µmol of substrate converted
per minute
µmol per min per mg prot
Control Silica (10 µg ml−1) Silica (20 µg ml−1)
Lgul
A 364.9 329.3 334.7
B 356. 316.9 300.9
C 370.3 336.5 238.6
D 366.7 349.0 306.2
Mean 364.5 332.9 295.1
Std deviation 6.06 13.40 40.5
Fold change 0.91 0.81
t test vs. control 0.011 0.040
IDHC
A 21.5 23.5 14.5
B 19.5 29.5 16.5
C 31.5 21.0 20.5
D 33.5 27.5 11.0
Mean 26.5 25.37 15.62
Std deviation 7.02 3.84 3.97
Fold change 0.96 0.59
t test vs. control 0.791 0.045
Biliverdin reductase
A 1.0 0.5 0.77
B 0.82 0.68 0.68
C 0.73 0.68 0.73
D 0.86 0.77 0.82
Mean 0.85 0.66 0.75
Std deviation 0.11 0.11 0.06
Fold change 0.77 0.88
t test vs. control 0.053 0.177
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Another enzyme that can be implicated, although indirectly,
in the control of DNA damage is lactoylglutathione lyase,83 as
it prevents glycation of nucleotides by destroying methyl-
glyoxal. As guanine glycation has been already observed with
zinc oxide nanoparticles,56 we first checked if the observed
decrease in the amount and activity of lactoylglutathione lyase
(spot h9) was correlated with an increased sensitivity to
methylglyoxal. The results, displayed in Fig. 6A and B, show no
significant difference in methylglyoxal sensitivity between
control cells and silica-treated cells.
If the hypothesis regarding the role of DNPH1 is correct, a
decrease in this protein may mean a decrease in detoxification
of damaged DNA and thus an increased sensitivity to DNA-
damaging agents detoxified via the nucleotide excision repair
(NER) pathway. To test this hypothesis, we examined the effect
of silica nanoparticles on the cellular sensitivity to styrene
oxide, a bulky nucleophilic agent inducing cell death and DNA
damage in other models.84,85 The results, displayed in Fig. 6C
and D, show that pre-treatment of macrophages with silica
nanoparticles induces an increased sensitivity to styrene oxide.
This cross-toxicity effect is not present on MPC11 cells, which
show a silica-induced increase in the cellular amount of
DNPH1 instead of the decrease observed in macrophages. To
obtain further insights into the alterations of the NER system
induced by silica nanoparticles, we investigated the changes in
the expression of some of the proteins of the system by RT-
qPCR. The results, displayed in Fig. 7, show a decrease in the
expression of some of these genes: Cockayne Syndrome
Protein A (CSA), Proliferating Cell Nuclear Antigen (PCNA),
DNA repair protein XRCC1, and DNA excision repair protein
(ERCC1) upon macrophage treatment with silica nanoparticles
at the LD20 dose. Only two genes (CSA and XRCC) show a
modulated response in the MPC11 cell line and here again at
the LD20 dose.
Fig. 3 Changes in the cell morphology and actin cytoskeleton. Three dimensional reconstructions of the F-actin cytoskeleton (visualized by phalloi-
din staining) are shown, allowing visualization of the surface ruffles of the cells. Top row: Control cells and cells treated for 24 hours with Ludox
TMA silica. Bottom row: Cells treated with fluorescent latex beads. Note the loss of surface spikes induced by silica but not by latex, showing that
the effect is not solely induced by the phagocytosis process per se.
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4. Discussion
One of the major problems in the field of nanotoxicology is
the variability of the results presented in the scientific litera-
ture. The variability of the nanomaterials, even if they bear the
same chemical name, and their poor characterization have
often been blamed as the main cause of this observed varia-
bility. However, in many cases both the cell types and the
nanoparticles used change from one study to another, and it is
difficult to evaluate the influence of each factor on the final
variability. Even worse, some cell lines such as those used in
the present study can be cultured in two different media,
namely RPMI 1640 and DMEM. When comparing our results
with those obtained by Panas et al.7 on the same cell line with
precipitated amorphous silica of very similar size (26 vs.
25 nm), we found a much higher cytotoxicity than they did.
However our cells are grown in RPMI 1640 while in their study
the cells were grown in DMEM, and it has been recently
demonstrated that such a medium change induces significant
changes in the cellular proteome and in the observed
responses to nanoparticles.86 This may be linked to the
already-described dependence of silica toxicity on metabolic
activity,87 which may be different between the rich DMEM
medium and the relatively poorer RPMI 1640 medium.
This being stated, the increased sensitivity of macrophages
to amorphous silica, which has been established in several
studies, both for nanoparticles e.g. ref. 5–7 and microparti-
cles12 is further confirmed in the present study.
In the case of amorphous silica, one factor that greatly
affects cytotoxicity is the presence of a protein corona, which
forms when silica is introduced into a protein-containing
medium such as culture media with bovine serum.88 It has
been shown that the presence of the corona decreases the tox-
icity of silica (e.g. in ref. 89 and 90). This means that in the
presence of proteins, the entity that is internalized is not a
bare silica particle, but a core–shell silica–protein particle,
which means in turn that in this case, adsorbed proteins are
introduced into the cell. It may be then questioned whether
such internalized proteins may affect cellular physiology.
Although such a hypothesis cannot strictly be ruled out, it
seems unlikely for two reasons. First the proteins adsorbed on
nanoparticles are often denatured,91,92 which means that they
Fig. 4 Study of the phagocytic index and of the mitochondrial trans-
membrane potential. Panel A: Proportion of phagocytic cells (in the
viable cell population only) for control cells or cells treated for 24 hours
with 10 or 20 µg ml−1 Ludox TMA silica. Panel B: Mean fluorescence of
phagocytic cells (in the viable cell population only) for control cells or
cells treated for 24 hours with 10 or 20 µg ml−1 Ludox TMA silica. Panel
C: Proportion of Rhodamine 123-positive cells in the total population
(white bars) or in the viable cell population only (dotted bars) for control
cells or cells treated for 24 hours with 10 or 20 µg ml−1 Ludox TMA
silica. Panel D: Mean Rhodamine 123 fluorescence (in the viable cell
population only) for control cells or cells treated for 24 hours with 10 or
20 µg ml−1 Ludox TMA silica. Symbols indicate the statistical significance
(Student’s t-test): *p < 0.05; †p < 0.01.
Fig. 5 Validation of the effects on signaling pathways. Panel A: Dose
dependent survival curve for RAW264.7 cells treated for 24 hours with
various concentrations of Ludox TMA silica, with (dotted lines) or
without co-treatment with the PKA inhibitor H89 (10 µM). Panel B: NO
production of RAW264.7 cells treated with Ludox TMA nanoparticles
only (black bars) or treated with nanoparticles and 100 ng ml−1 lipopoly-
saccharide (hatched bars). #Significant difference at p < 0.05 with the
Mann–Whitney U test but not the Student’s t-test (p = 0.08). †p < 0.01
according to the Student’s t-test. Panel C: IL6 production of RAW264.7
cells treated with Ludox TMA nanoparticles only (black bars) or treated
with nanoparticles and 100 ng ml−1 lipopolysaccharide (hatched bars).
Symbols indicate the statistical significance (Student’s t-test): *p < 0.05;
†p < 0.01; ††p < 0.001. Note the different scales for IL6 production for
cells treated with silica alone (left scale) or with silica and LPS (right
scale). Panel D: TNF-alpha production of RAW264.7 cells treated with
Ludox TMA nanoparticles only (black bars) or treated with nanoparticles
and 100 ng ml−1 lipopolysaccharide (hatched bars). Symbols indicate the
statistical significance (Student’s t-test): *p < 0.05; †p < 0.01; ††p < 0.001.
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lose their functions. Second, silica nanoparticles are interna-
lized in lysosomes14 which are in an acidic environment where
massive protein degradation occurs. Consequently, a func-
tional effect of the corona inside the cells seems rather
unlikely.
As another example of the variability of the results pub-
lished in the literature, proteomic studies on the cellular
responses to silica nanoparticles have been published pre-
viously42,93 and have shown widely different results and even
results different from those presented in the present study.
However, the low number of common responses detected in
the present study between two different cell lines at equal
effect dose or at identical doses clearly demonstrates that cellu-
lar responses are widely different from one cell type to
another, and such cell type-specific effects are the main expla-
nation for the different responses reported using proteomic
studies.
There are however discrepancies that remain, even when
working with the same cell line in the same culture medium
and with similar nanoparticles. One example can be found in
the synergy between silica and LPS for NO production. In our
study we found a negative synergy (silica decreases the LPS-
induced NO production) while Di Cristo et al. found a positive
synergy.30 Several factors can explain this discordance in the
results: (i) the duration of the LPS treatment (24 hours in our
case instead of 48 hours in the Di Cristo et al. study), (ii) the
concentration of silica used (10 µg cm−2 in the Di Cristo et al.
study instead of 4 µg cm−2 in our case) and (iii) the fact that in
this precise case Di Cristo et al. used a suboptimal LPS concen-
tration (10 ng ml−1) instead of the 100 ng ml−1 concentration
that we used and also gave full NO production in the Di Cristo
et al. study. While the duration of the treatment may explain
the differences in the absolute NO concentration found
(20 mM in their case instead of 9.5 mM in our study), the
Fig. 6 Validation of cross toxic effects. In these experiments the cells
were pre-treated with 0, 10 or 20 µg ml−1 Ludox TMA nanoparticles for
6 hours, then the toxic agent was added for a further 18 hours. Cell via-
bility was assessed by dye exclusion after this total 24 hour treatment.
Panel A: Survival curve for RAW264.7 cells co treated with silica and
methylglyoxal (MG). Circles: Control cells (not treated with silica).
Squares: Cells treated with 10 µg ml−1 silica. Triangles: Cells treated with
20 µg ml−1 silica. Diamonds and dotted line: Cells treated with 20 µg
ml−1 silica, with correction of the mortality induced by silica alone. No
statistically significant effect can be detected for cells treated with 10 µg
ml−1 silica, and after correction of the mortality induced by silica alone,
a moderate but statistically significant effect (p < 0.05) can be detected
for cells treated with 20 µg ml−1 silica only at 600 µM methylglyoxal.
Panel B: Same as panel A, but for MPC11 cells. No statistically significant
effect could be detected. Panel C: Survival curve for RAW264.7 cells co-
treated with silica and styrene oxide (StOx). Circles: Control cells (not
treated with silica). Squares: Cells treated with 10 µg ml−1 silica.
Triangles: Cells treated with 20 µg ml−1 silica. Diamonds and dotted line:
Cells treated with 20 µg ml−1 silica, with correction of the mortality
induced by silica alone. Except for the 0 µM styrene oxide point, all
points are statistically different between the cells treated with 20 µg
ml−1 silica (p < 0.01 for 100, 200, 300 µM styrene oxide, p < 0.05 for 500
and 750 µM styrene oxide) and cells treated with styrene oxide alone,
even after correction of the mortality induced by silica alone. For the
cells treated with 10 µg ml−1 silica, all points except the 0 µM styrene
oxide point are statistically different from the control (p < 0.01). Panel D:
Same as panel C, but for MPC11 cells. No statistically significant effect
could be detected.
Fig. 7 Expression analysis by RT-qPCR of genes involved in the nucleo-
tide excision repair (NER) pathway. The expression of six genes involved
in the NER pathway was monitored by RT-qPCR for RAW264.7 and
MPC11 cells treated with Ludox TMA silica nanoparticles. White bars:
Control cells. Hatched bars: Cells treated for 24 hours with 10 µg ml−1
silica. Black bars: Cells treated for 24 hours with 20 µg ml−1 silica.
Dotted bars: Cells treated for 24 hours with 100 µg ml−1 silica. *p < 0.05
in the Student’s t-test.
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opposite synergies found probably depend on the last two
factors. Indeed, a positive synergy will be impossible to
observe if the maximal stimulation is already reached. In
addition, the silica dose used in the Di Cristo et al. study is
fairly important and induces strong membrane permeability
(50% at 24 hours). As this parameter is the one tested by the
viability assay that we used (trypan blue exclusion), such a con-
dition corresponds to the LD50 in our system. Such an acti-
vation of the proinflammatory functions of macrophages at
toxic concentrations has already been described for silica11
and for other nanoparticles,94 and may contribute to explain
the differences between the two sets of results on the silica-
LPS synergy.
In order to extend our observations on the TLR axis, we also
measured the release of the two inflammatory cytokines IL6
and TNF. While IL6 showed the same response as NO pro-
duction (weak induction by silica alone and strong reduction
by silica of the LPS-induced response) TNF did not show the
same response pattern. This discordance between the two cyto-
kine responses has been observed previously in the case of
copper oxide nanoparticles.48
One of the more interesting outcomes of the proteomic ana-
lysis lies in the proteins involved, directly or indirectly, in the
DNA repair pathway. Such proteins include PCNA, DNPH1 and
lactoylglutathione lyase. Regarding lactoylglutathione lyase, we
did not observe any cross toxicity between silica and methyl-
glyoxal, opposite to what was observed with zinc nano-
particles.56 The decrease of PCNA and DNPH1 suggested
however a decrease in the efficiency of the NER pathway, which
resulted in a higher sensitivity to bulky DNA alkylating agents.
This sensitivity was however observed only on the sensitive cell
type (macrophage) and not on the less sensitive MPC11 cell
line. Such a cross sensitivity may be relevant for pulmonary
toxicity, as it could induce a decrease in the number of viable
lung macrophages if they are exposed both to silica nano-
particles and to DNA alkylating agents, such as those con-
tained in tobacco smoke or combustion particles at a larger
sense. A similar cross toxicity between insoluble nanoparticles
and DNA alkylating agents has been previously observed with
titanium dioxide.95 Genotoxicity has been previously described
for silica nanoparticles,25,27 but has been observed only at
high, cytotoxic concentrations.
These cross toxic effects between nanoparticles and chemi-
cals have been described with metallic ions such as
cadmium39 and lead,40 but our work and the one of Armand
et al. extend it to organic chemicals. The sequential treatment
used (nanoparticles first, then chemicals) is not in favor of a
direct trojan horse effect, i.e. an adsorption of the chemical on
the nanoparticles leading to a better penetration in the cells
and an intracellular release of the adsorbed chemical. It is
more in favor of a synergistic effect, i.e. an alteration of the cel-
lular physiology by the nanoparticle which renders the cell
more sensitive to the chemical of interest.
Such studies of cross effects are important in a safe by
design perspective. Primary determinants of cellular toxicity are
of course of crucial importance, and have been recently
described for silica.20 They are however not sufficient, as the
real use of the products involves co-expositions that are difficult
to predict and may vary greatly, e.g. according to lifestyle. In
such a frame, wide-scope studies such as omics studies are able
to provide valuable insights, provided that they are fully inter-
preted down to the protein level and not only to the pathway
level, and provided that their predictions are tested.
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